Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS

BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) is a fatal immunological syndrome resulting from excessive production of inflammatory cytokines. The conventional therapies for HLH, which are based on cytotoxic agents, are not always efficacious and safe, especially in patients with severe immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiang, Zhu, Xueling, Zhou, Xiaotang, Xie, Yirui, Xiang, Dairong, Wan, Zhikai, Huang, Ying, Zhu, Biao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573961/
https://www.ncbi.nlm.nih.gov/pubmed/36263041
http://dx.doi.org/10.3389/fimmu.2022.1012643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573961/
https://www.ncbi.nlm.nih.gov/pubmed/36263041
http://dx.doi.org/10.3389/fimmu.2022.1012643

Ejemplares similares